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Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a
number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum
agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between
individuals, it is hypothesized that an individual’s specific genetic variants could impact the regulation of genes
involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect
CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of
CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic)
predictors of CIPN and discuss the means to facilitate progress in this field.
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Introduction
Chemotherapy-induced peripheral neuropathy (CIPN), a com-
mon side effect of anti-neoplastic agents, significantly de-
creases quality of life (QOL) in patients with cancer. CIPN
symptoms include numbness, tingling, and pain especially in
the hands and feet. This in turn is associated with an inability
to complete activities of daily living and with falling [1].
Development of CIPN may lead to dose modifications, de-
creased patient adherence, and treatment interruptions or dis-
continuation, thereby potentially impacting oncologic out-
comes negatively. Those with CIPN also report increased un-
employment and decreased annual income, further demon-
strating the negative impact that CIPN can have on patients
[2].
A meta-analysis involving over 4000 patients estimated
CIPN prevalence to be about 68% by the end of the first
month of chemotherapy and 30% at 6 months [3]. Drugs com-
monly implicated in the development of CIPN include plati-
num drugs, taxanes, vinca alkaloids, bortezomib, and thalido-
mide analogues.
Since the response to the same drug can vary between
individuals, it is hypothesized that a patient’s specific genetic
variants could impact the regulation of genes involved in drug
pharmacokinetics (PK), ion channel functioning, neurotoxici-
ty, and DNA repair, which may in turn affect CIPN develop-
ment and severity. The goal of this manuscript was to summa-
rize the known biological (molecular and genomic) predictors
of CIPN and discuss means to facilitate progress in the under-
standing and eventual management of CIPN.
Demographic and clinical predictors of CIPN
While there are established clinical risk factors for CIPN, none
accurately predicts the severity of CIPN that an individual
patient will have [4]. Cumulative dose is a strong risk factor
for the development of CIPN with most neurotoxic anti-
neoplastic drugs. Patients of older age may be more at risk
for developing neurotoxicity [5–7]; however, other studies
have not found age to be associated with greater CIPN inci-
dence [8, 9]. These differing results may be due to confound-
ing comorbidities. Obese cancer patients with CIPN experi-
ence higher levels of neuropathy burden [10]. Diabetic pa-
tients report a higher grade of CIPN, particularly with taxanes
while patients with autoimmune diseases report less severe
CIPN [6]. African-Americans have a higher incidence of
CIPN following taxane treatment in comparison with other
racial groups [11].
Pathophysiology and biological predictors of CIPN Table 1
summarizes the mechanisms of action of chemotherapeutic
agents and reported genetic polymorphisms associated with
CIPN. The molecular targets and pathways of CIPN are de-
scribed in Fig. 1.
Platinum compounds Platinum compounds interfere with tu-
mor cell proliferation, resulting in damage to non-dividing,
post-mitotic peripheral neural tissue. This damage may be
associated with sensory neuropathy with anterograde axonal
degeneration, first described for cisplatin concentrations in
tissue collected posthumously [12, 45]. Whether this is true
for systemic concentrations is less well understood. In addi-
tion to chronic neuropathy, acute neuropathy presenting as
cold-induced dysesthesia is unique for oxaliplatin and is
thought to be related to the rapid generation of oxalate metab-
olites [12].
Indirect evidence indicates that neuropathy may be attrib-
utable to systemic platinum drug PK. It is suggested that in-
creased fractionation of cisplatin in the bleomycin, etoposide,
and cisplatin (BEP) regimen may reduce neurotoxicity with
the 3-day regimen producing less acute and late sensory neu-
ropathy than the 5-day with equivalent anti-cancer efficacy
[46, 47].
Preclinical studies on the association between drug trans-
porters and oxaliplatin-induced neuropathy in mice with ge-
netic knockout of the organic cation transporter 2 (OCT2)
strongly suggest that platinum accumulation is related to the
activity of this transporter [48], suggesting that any indirect
association between systemic concentrations and neuropathy
would likely have to account for the magnitude of uptake
transport into the dorsal root ganglion (DRG). Dasatinib is
being investigated for its role in minimizing CIPN as it in-
hibits the activity of OCT2, which could decrease oxaliplatin
uptake in the DRG [49]. However, a population-
pharmacokinetic model did not detect any association be-
tween PK parameters of the parent compound or the free
oxaliplatin concentrations and neuropathy incidence [50]; oth-
er small pilot studies have also not detected a relationship [51,
52]. Yet, in a randomized trial of reduced glutathione (GSH),
co-administration, decreased neuropathy incidence, and in-
creased oxaliplatin clearance were reported [53].
A number of aberrations identified as potential future ther-
apeutic targets include several single nucleotide polymor-
phisms (SNPs) such as ERCC1, ERCC2, XRCC1, CCNH,
GPX7, and ABCC4, which may play critical roles in neuro-
toxicity, as described in Table 1 and Fig. 1 [13–19]. One
genomically targeted therapeutic intervention focuses on the
protein, apurinic/apyrimidinic endonuclease (APE-1). APE-1
is critical in the DNA base excision repair pathway and oxi-
dative stress response, thereby mitigating chemotherapy-
induced neuronal DNA damage, especially from platinum
agents [33]. Early phase clinical trials are underway to en-
hance anti-oxidant effects of APE-1 and inhibit damaging
signals such as ERK-1/2 [54]. Early studies investigating the
drug, APX3330, suggest a neuroprotective benefit similar to
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the genetic APE-1 overexpression. This is achieved without
minimizing chemotherapeutic efficacy by reducing redox sig-
naling and improving DNA repair in sensory neurons [33].
Taxanes
Taxanes, which are spindle poisons, accumulate in the
soma of sensory neurons of dorsal root ganglia. A retro-
grade “dying back” process is commonly observed, which
typically starts at distal nerve endings, and is subsequent-
ly associated with the Schwann cell, neuronal body, or
axonal transport changes. This sequence of alterations is
believed to contribute to neurotoxicity. Genomic predic-
tors of paclitaxel- and docetaxel-associated neuropathy
are shown in Table 1.
The genetic prediction of paclitaxel-induced peripheral
neuropathy has been extensively studied and recently
reviewed [55]. Though candidate SNPs in cytochrome P450
(CYP) CYP2C8 [21], ABCB1 [21, 22], and TUBB2A [22]
have been associated with neuropathy, none have been vali-
dated for use in clinical care due to inconsistent replication.
Strong evidence links paclitaxel PK to the incidence of pe-
ripheral neuropathy [20, 56], including a randomized clinical
trial demonstrating that exposure-guided paclitaxel dosing
significantly reduces peripheral neuropathy incidence [57].
This PK association likely explains the reported associations
for the putatively low-activity CYP2C8*3 variant described
above and the increased risk of paclitaxel-induced neuropathy
in patients receiving the strong CYP2C8 inhibitor, clopidogrel
[58, 59]. Genome-wide association studies (GWAS) have
identified candidates for attempted replication, including
SNPs in FGD4 [23] and EPHA5 [21]. SNPs in several
EPHA genes including EPHA4, EPHA5, and EPHA6 [1, 5]
have been associated with paclitaxel-induced neuropathy,
strongly suggesting this gene family is involved in neuropathy
predisposition [60]. Many SNPs discovered via GWAS have
been in genes involved in neurodevelopment, particularly
those associated with hereditary neuropathy conditions [61]
including ARHGEF10 [24]. Other SNPs reported from
GWAS have not been independently replicated [11, 34,
62–65]. Preclinical studies indicate that nilotinib may reduce
paclitaxel-induced peripheral neuropathy through a non-
competitive mechanism that allows paclitaxel to effectively
attack cancer cells while inhibiting the solute carrier organic
anion-transporting polypeptide B2 (OATP1B2). Suppression
of OATP1B2 activity was found to minimize peripheral neu-
ropathy [66].
Few pharmacogenetic studies have been conducted for
docetaxel-induced peripheral neuropathy. Candidate SNPs in
ABCB1 [25, 26] and GSTP1 [25, 27] have been reported, but
not yet validated [67]. The only completed GWAS reported a
variant in VAC14 that increased neuropathy risk and was con-
firmed to decrease neurite branching in vitro and increase
mouse neuropathy sensitivity in VAC14 knockout studies
[68, 69]. There have been no pharmacogenetic studies of neu-
ropathy caused by albumin-bound paclitaxel (nab-paclitaxel)
or cabazitaxel.
Figure 1 Molecular targets and pathways of CIPN. Affected neurons:
dorsal root ganglion (∗); sensory neurons (∇); motor neurons (⊕);
central projections of primary afferent neurons (σ). Abbreviations:
VDAC voltage-dependent anion channels, Ca2+ calcium ions, TRP
transient receptor potential
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Vinca alkaloids
Vinca alkaloids, such as vincristine and vinblastine, block
microtubule polymerization, consequently disrupting mitotic
spindle formation and rendering the cell unable to divide.
Mutations inCEP72 andCYP3A5 have beenmost extensively
studied as factors possibly influencing the development of
vincristine-induced neuropathy. Studies have demonstrated
that SNPs that reduce CEP72 expression may lead to the de-
velopment of neuropathy in patients on vincristine [29, 30],
although subsequent studies were unable to consistently re-
produce this finding [31, 32]. Vincristine is primarily metab-
olized by CYP3A4 and 3A5. Polymorphisms of CYP3A5 are
common, with the CYP3A5*1/*1 genotype being associated
with expression of CYP3A5 and is more common in African-
Americans. The CYP3A5*3/*3 genotype is associated with
non-expression of CYP3A5 and is more common in
Caucasians [35, 36]. Early studies suggested a possible asso-
ciation between CYP3A5 genotypes and vincristine-induced
peripheral neuropathy [34, 37]. The CYP3A5*1/*1 genotype
is associated with a lower incidence of neuropathy compared
with the CYP3A5*3/*3 genotype [38]. However, others have
also reported no effect of CYP3A5 genotype on the develop-
ment of neuropathy [33, 39]. Early evidence suggests that
vincristine PK may be associated with neuropathy [18]; how-
ever, validation has been challenging [35, 40].
Table 1 Reported genetic polymorphisms associated with chemotherapy-induced peripheral neuropathy
Agent Mechanism Gene (-SNP) Functional pathway Reference
Platinum Interfere with tumor cell proliferation by forming
DNA-platinum adducts that accumulate in the DRG
and in peripheral neurons.
ERCC1 DNA repair [13]
ERCC2 DNA repair [14, 15]
XRCC1 Cell cycle progression, RNA
transcription, DNA repair, and
possibly repair after platinum induced
damage to DRG
[15, 16]
CCNH Oxidative damage protection [17, 18]
GPX7 Transporter enzyme [19]
ABCC4 Glutathione [19]
Paclitaxel Stabilization of microtubules and inhibition of
depolymerization, forming abnormal microtubule
bundles in the cytoplasm and producing mitotic
spindle disruption and apoptosis [21].
CYP2C8 Metabolizes paclitaxel [21]
ABCB1 Cellular and systemic drug efflux
transporter
[21, 22]
TUBB2A Molecular target for paclitaxel [22]
FGD4 Myelin production [23]
EPHA4, 5, 6 Nervous system development / repair [1, 5, 21]
ARHGEF10 Neurodevelopment [24]
Docetaxel Stabilization of microtubules and inhibition of
depolymerization, forming abnormal microtubule
bundles in the cytoplasm and producing mitotic
spindle disruption and apoptosis.
ABCB1 Cellular and systemic drug efflux
transporter
[25, 26]
GSTP1 Drug conjugation and detoxification [25, 27]
VAC14 Neurodevelopment [53, 54]
Vinca
alkaloids
Promote disassembly of microtubules by binding to
tubulin during S phase and preventing microtubule
polymerization, disrupting mitotic spindle formation
in M phase, and rendering cell unable to divide.
CEP72 Microtubule formation [29–32]
CYP3A5 Vincristine metabolism [33–40]
Bortezomib Indirectly polymerize tubulin, causing microtubule
stabilization, axonal transport inhibition, and G2-M
phase cell cycle arrest.
CTLA4 rs4553808 Immune function [41]
PSMB1 rs1474642 Drug binding [41]







Thalidomide Inhibit production of IL-6 (growth factor), blocks
the cell growth-stimulating CD147/MCT1 protein
complex from binding to cereblon, activate
apoptotic pathways through caspase 8-mediated cell
death, and activates T cells to produce IL-2
augmenting NK-dependent cytotoxicity.
ABCA1 Neuroinflammation, neurodegeneration [43]
ICAM1 Myelinogenesis, nerve regeneration [43]
PPARD Promote mitochondrial biogenesis [43]
SERPINB2 Proteostasis, neuro-cytoprotection [43]
SLC12A6 K & Cl cotransporter [43]
GSTT1 Drug conjugation and detoxification [44]
3732 Support Care Cancer (2019) 27:3729–3737
Bortezomib
The proteasome inhibitor, bortezomib, promotes G2-M cell
cycle arrest and apoptosis through the disruption of the
ubiquitin-proteasome pathway which degrades dysfunctional
intracellular proteins. Subcutaneous administration of
bortezomib has been found to greatly reduce reported
bortezomib-induced peripheral neuropathy in comparison
with intravenous administration, as well as the reduction of
other adverse effects [37]. Despite the same treatment efficacy,
the prevalence of peripheral neuropathy in the population
treated with subcutaneous injection is 38% in comparison
with 53% in those treated with intravenous bortezomib [37].
The exact mechanism of bortezomib-induced peripheral neu-
ropathy is unknown. SNPs in CTLA4 rs4553808 and PSMB1
rs1474642 have been reported to be associated with
bortezomib-induced neuropathy [41]. A GWAS study identi-
fied 4 new loci that were associated with bortezomib-induced
peripheral neuropathy, found in genes involved in the devel-
opment and function of the nervous system includingCDH13,
DCC, and TENM3 [39]. Another GWAS study identified a
gene locus mapping to PKNOX1 and in close proximity to
CBS at 21q22.3 that was correlated with the severe
bortezomib-induced toxicity [42]. However, additional studies
to validate these findings are needed prior to establishing these
genes for study as therapeutic targets.
Thalidomide
Thalidomide, an immunomodulatory agent, prevents cell pro-
liferation through inhibition of angiogenesis as well as alter-
ation of the immune system through multiple mechanisms
including inhibition of interleukin (IL)-6 production, activa-
tion of caspase 8–mediated apoptosis, and increased produc-
tion of IL-2 through T cell activation. Based on a meta-anal-
ysis, thalidomide-related peripheral neuropathy has been de-
scribed in 63.5% of patients [3]. Several SNPs have been
found to be associated with thalidomide-related peripheral
neuropathy: ABCA1, ICAM1, PPARD, SERPINB2, and
SLC12A6 [43]. In addition, a SNP in GSTT1 predicted the
frequency of neuropathy [44]. Another study was unable to
find associations between 300,000 exome SNPs and
thalidomide-related peripheral neuropathy [70]. Studies of
lenalidomide, a sister drug of thalidomide with similar
antiangiogenic immunomodulatory mechanisms of action,
demonstrate significantly lower incidence of peripheral neu-
ropathy [71]. The mechanism is hypothesized to be a PK
effect similar to that observed with the platinum compounds;
the half maximal inhibitory concentration (IC50) of
lenalidomide is almost 500 times less than that of thalidomide
(0.4 μmol/L vs. 194 μmol/L, respectively) [72]. This marked
difference reflects the much lower serum concentrations of
lenalidomide required for target activity in comparison with
thalidomide and highlights the potency of lenalidomide.
Limitations of current studies
Biomarker discovery studies of CIPN have several limitations,
the primary being a lack of an objectively assessable, univer-
sally accepted CIPN phenotype [73]. Varying methods to de-
fine the phenotypes, such as clinician-assessed National
Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) and grading classifications, have com-
plicated the comparison of multiple study findings with one
another. In addition, discordance across GWAS studies is a
significant limitation [73]. Collapsing different phenotypes
into a single definition may limit the ability to identify genetic
predictor of any single phenotype. For instance, it is likely that
a genetic predictor of neuropathic pain is distinct from a pre-
dictor of sensory versus motor neuropathy [74]. Failing to
adjust for clinical (particularly cumulative dose received) or
environmental differences may have impeded the precision of
reported findings.
Data from patients treated with combination therapies rath-
er than a single agent may have contributed to the inconsistent
results across studies. While some SNPs may predispose pa-
tients to CIPN regardless of the neurotoxic agent, each class of
agents, and perhaps each agent within that class, is likely to
have independent risk factors. As one illustrative example,
analyses have combined patients taking paclitaxel or docetax-
el and included SNPs in CYP2C8, which is only involved in
paclitaxel metabolism but not docetaxel [28]. Labeling how
all taxanes are involved with CYP2C8 would not be
appropriate.
A well-powered sample size is the cornerstone to the gen-
eration of valuable genetic association studies, granting the
study enough power to confirm the correlations. Currently,
most studies are retrospective in nature and are limited to the
fixed sample size of the prospective study from which they
were conducted, leading to underpowered analyses. Further,
because a smaller number of toxicities occur in studies with
smaller sample sizes, the ability to produce extensive data on
toxicity for further analysis is restricted [73]. An additional
factor to inspect is the genetic ancestry of the study popula-
tion, reflected by distinct allele frequencies in the variations
being investigated. Since these frequencies are due to the an-
cestral history of the populations, they must be accounted for
in the association analyses. Otherwise, observed differences
between those experiencing neuropathy and those who are not
may simply be due to the ancestral composition of the com-
pared groups rather than differences in chronic toxicities.
The reporting of genetic association studies should be as
transparent as possible. The STrengthening and the REporting
of Genetic Association Studies (STREGA) recommendations
promote the transparency, excellence, and thoroughness of
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genetic association study reporting [75]. Studies should also
provide essential information such as quality error and call
rates as they may have a significant effect on the ability to
detect linkage or association.
Novel analytical approaches
Besides traditional approaches, analyses of gene expression
(i.e., transcriptomics) or differential gene expression, protein
expression (i.e., proteomics), or biochemical metabolite con-
centrations (i.e., metabolomics) may be useful for predicting
future neuropathy occurrence, but data on applying these tech-
niques to measure toxicity from cancer treatments is scarce
[76]. Discovery-phase candidates from proteomic and
metabolomic analyses require independent validation prior
to translation into clinical practice.
Recent advances in human stem cell technology have
allowed for increasingly detailed in vitro studies of CIPN.
Adult human somatic cells (often skin fibroblasts or lympho-
cytes) can be reprogrammed into induced pluripotent stem
cells (iPSCs) [77], which then may differentiate into specific
cell types of interest. Neurons produced from these stem cell
differentiation protocols allow researchers to harness human
biology and genetics, including within specific patient popu-
lations such as patients with CIPN.
Future directions
To mitigate CIPN’s detrimental impact on patient quality of
life, a clear understanding of the molecular pathways under-
lying its development and natural history is necessary. This
understanding will support the development of targeted clini-
cal strategies [78]. Building on the foundational work done to
date, the growth of novel research platforms will allow for
new ways of interrogating these pathways. Table 2 provides
a list of recommendations for future genetic studies of CIPN,
which aim to ensure the translation of research findings into
clinical decision-making. However, none of these biomarkers
are currently ready to be translated into routine practice. To
continue to make progress on understanding predictors of
CIPN and predictors of response to various therapeutic strat-
egies, the following strategies will be helpful: new methodo-
logical approaches to study genomics and molecular path-
ways, data sharing, and real-world data, as well as multidisci-
plinary funding and collaboration.
New methodological approaches from complex data anal-
ysis techniques can be applied to the intersecting effects of
symptom biology. For instance, cluster analyses may include
the impact of symptoms on the condition, manifestation of
toxicities, and interaction of toxicities on the overall condition.
Dissection of symptoms to underlying biology using genome-
wide approaches can yield information on polymorphisms
that may affect innate risk and response, as well as adaptive
variability in gene expression resulting in individually dynam-
ic pathobiology. Although genomic (genotyping, gene expres-
sion, and epigenetic) approaches are useful for dissecting ef-
fects and interactions of the tumor, treatment, and host suscep-
tibility factors, these studies must involve a large number of
subjects. As methodology improves power with smaller sam-
ple sizes, these studies may be linked with those conducted to
examine primary mechanisms and toxicities [79].
To make significant progress in CIPN research, clinical
research networks can be developed into data repositories
where variable interactions such as pharmacogenomics,
pharmacoproteomics, gene expression/proteomic changes in
human specimens, and patient-reported outcomes can be
linked to clinical phenotypes. This will ultimately move the
field towards population-based rather than clinic-specific re-
search, while encouraging standardization of data measures.
Such networks are exemplified by NIH initiatives using
public-private partnering mechanisms to provide publically
available resources such as PhenX (the Phenotyping and
Exposures project) and PROMIS (Patient-Reported
Outcomes Measurement Information System).
Lastly, joint funding of proposals with a variety of funding
agencies such as the National Cancer Institute, National
Institute of Neurological Disorders and Stroke, and other re-
search funders with overlapping missions has been considered
an approach to leverage funds. Other examples of recent fa-
cilitation of larger scientific endeavors include the following:
a growing investment in clinical research networks such as
Patient-Based Research Networks; the linking of Clinical
and Translational Study Award–supported academic sites;
and complementary electronic resources, such as Clinical
ResearchNetworks. These encourage the expansion of current
clinical research networks by conducting studies across
Table 2 Methodological recommendations for future research studies
on biological predictors of CIPN
✓ Distinguishing the various phenotypes of CIPN (motor vs. sensory vs.
neuropathic pain), in order to support consistency in the classification
of “cases” across studies; studies may also want to target high-risk
patients (e.g., patients who develop peripheral severe neuropathy after
first few doses of treatment).
✓ Longitudinal assessment of CIPN, including pre-treatment assessment.
✓ Prospective research design is ideal, to ensure the collection of known
relevant clinical factors including cumulative dose, drug exposure,
diabetes, and race.
✓ Studies should clearly report the justification of genomic predictors
interrogated.
✓ Consistent reporting of the process used for genotyping.
✓ Collaboration between study centers to increase sample size and
confirm the generalizability of findings.
✓ Collaboration between patients, clinicians, and translational
researchers will support the application of innovative methods to
address clinically meaningful outcomes.
✓ Development and testing of interventions targeted at implicated
pathways.
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multiple research sites. Collaboration across sites through
these mechanisms makes it feasible to increase sample size,
increase generalizability, facilitate standardized data collec-
tion methods, and promote scientific exchange across pro-
grams and study sites.
Conclusions
A number of clinical and genetic predictors have been identi-
fied, yet we are still unable to adequately prevent or treat
CIPN. Future work is needed to develop a CIPN risk model
where the drug, genomic, and clinical data are incorporated to
better understand the risk of various neurotoxic therapies. In
summary, advances in research methodologies, new technol-
ogies, and creative partnering relationships enhance the feasi-
bility of these proposed strategies through efficiency in con-
duct as well as the economy of funding.
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